Kingswood Wealth Advisors LLC Has $267,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Kingswood Wealth Advisors LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 12.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,914 shares of the company’s stock after selling 570 shares during the period. Kingswood Wealth Advisors LLC’s holdings in CRISPR Therapeutics were worth $267,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Congress Asset Management Co. MA grew its stake in CRISPR Therapeutics by 60.3% in the 1st quarter. Congress Asset Management Co. MA now owns 64,605 shares of the company’s stock valued at $4,403,000 after buying an additional 24,303 shares during the last quarter. PBCay One RSC Ltd bought a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $10,329,000. Invesco Ltd. lifted its position in shares of CRISPR Therapeutics by 1.5% during the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock worth $6,179,000 after purchasing an additional 2,061 shares during the last quarter. ARK Investment Management LLC boosted its stake in CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after purchasing an additional 1,372,986 shares during the period. Finally, Norges Bank acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at approximately $38,661,000. 69.20% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CRSP. Oppenheimer reduced their price objective on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. Mizuho upped their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Wells Fargo & Company cut their price target on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. Finally, Piper Sandler restated an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $75.71.

Insiders Place Their Bets

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Down 2.5 %

NASDAQ:CRSP opened at $54.01 on Friday. The firm has a market capitalization of $4.59 billion, a price-to-earnings ratio of -19.86 and a beta of 1.78. The business’s 50-day moving average price is $56.72 and its two-hundred day moving average price is $64.46. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. During the same quarter in the previous year, the business posted ($0.67) EPS. The business’s revenue for the quarter was down 99.5% on a year-over-year basis. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.